| All patients n = 63 | Single organ involvement, n = 18 | Multiple organ involvement n = 45 | P value* |
---|---|---|---|---|
Age, years | 58 (45–68) | 59 (44–75) | 57 (45–65) | 0.330 |
Sex, female | 38 (60.3) | 9 (50.0) | 29 (64.4) | 0.394 |
Body mass index, kg/m2 | 21.4 (20.1–23.8) | 21.9 (20.4–23.1) | 21.4 (19.9–23.8) | 0.897 |
Smoking, ever-smoker | 31 (49.2) | 9 (50.0) | 22 (48.9) | 1.000 |
Number of affected organs, 1/2/3/4/5 | 18/30/13/1/1 | 18/0/0/0/0 | 0/30/13/1/1 | < 0.001 |
Affected organs | Â | Â | Â | Â |
 Lungsa | 62 (98.4) | 17 (94.4) | 45 (100.0) | 0.286 |
 Eyes | 33 (52.4) | 1 (5.6) | 32 (71.1) | < 0.001 |
 Skin | 10 (15.9) | 0 | 10 (22.2) | 0.051 |
 Heart | 4 (6.3) | 0 | 4 (8.9) | 0.317 |
 Othersb | 13 (20.6) | 0 | 13 (28.9) | 0.013 |
Histological diagnosis | 54 (85.7) | 16 (88.9) | 38 (84.4) | 1.000 |
Serum ACE, IU/L | 19.3 (14.5–25.3) | 16.6 (14.2–21.5) | 21.4 (15.1–25.4) | 0.122 |
Radiographic stage, 0/I/II/III/IV | 1/21/36/4/1 | 1/6/9/1/1 | 0/15/27/3/0 | 0.802 |
Pulmonary function tests (n = 61) |  |  |  |  |
 FVC, L | 2.76 (2.34–3.40) | 3.00 (2.43–3.49) | 2.75 (2.33–3.30) | 0.389 |
 FVC, % predicted | 94.9 (88.1-100.7) | 96.4 (90.8-104.9) | 94.1 (87.5-100.3) | 0.187 |
 FEV1, L | 2.10 (1.82–2.79) | 2.55 (1.92–3.36) | 2.10 (1.81–2.66) | 0.385 |
 FEV1, % predicted | 90.3 (77.4-100.2) | 89.5 (78.2–98.8) | 91.1 (76.1-100.5) | 0.915 |
 FEV1/FVC, % | 77.9 (74.3–83.8) | 78.2 (74.8–82.8) | 77.9 (72.9–85.1) | 0.812 |
Bronchoalveolar lavage (n = 62) |  |  |  |  |
 Total cells, ×105/ml | 0.96 (0.61–1.48) | 1.00 (0.51–1.51) | 0.93 (0.68–1.47) | 0.561 |
 Lymphocytes, % | 11.9 (8.2–22.9) | 19.0 (5.9–26.5) | 11.5 (8.3–19.9) | 0.852 |
 CD4/CD8 ratio | 5.02 (3.30–7.75) | 4.58 (3.30–6.49) | 5.16 (3.34–7.91) | 0.841 |
 Treatment, none/CS/CS + azathioprine | 50/12/1 | 17/1/0 | 33/11/1 | 0.190 |